Cingulate Inc.

NASDAQ (USD): Cingulate Inc. (CING)

Last Price

4.82

Today's Change

-0.05 (1.02%)

Day's Change

4.80 - 4.94

Trading Volume

23,308

Profile
CING

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Shane J. Schaffer Pharm.D. Dr. Shane J. Schaffer Pharm.D.

Full Time Employees:  13 13

IPO Date:  2021-12-08 2021-12-08

CIK:  0001862150 0001862150

ISIN:  US17248W2044 US17248W2044

CUSIP:  17248W105 17248W105

Beta:  -0.93 -0.93

Last Dividend:  0.00 0.00

Dcf Diff:  8.28 8.28

Dcf:  -3.41 -3.41

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Address

1901 West 47th Place,
Kansas City, KS 66205, US

913 942 2300

http://www.cingulate.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment